10:24 AM EDT, 09/09/2024 (MT Newswires) -- GSK (GSK) said Monday that data from the SWIFT-1 and SWIFT-2 phase 3 trials evaluating the efficacy and safety of depemokimab compared with placebo in adults and adolescents with severe asthma showed that both trials met their primary endpoints.

The data, presented at the European Respiratory Society International Conference in Austria, showed "statistically significant reductions in the [annualized] rate of clinically significant exacerbations (asthma attacks) over 52 weeks versus placebo, with the pre-specified pooled analysis showing a significant 54% reduction in exacerbations," the company said.

The trials are duplicate studies and have the same primary and secondary endpoints, GSK said.

Depemokimab given every six months "produced sustained suppression of a key marker of type 2 inflammation, a driver of asthma attacks and [hospitalizations,]" the company said.

The trial results will support regulatory filings globally, GSK said, adding that depemokimab is not approved anywhere in the world.

Price: 43.52, Change: -0.15, Percent Change: -0.34